IGC Pharma, Inc. (IGC) Stock Ticker
IGC right now
Market factors today
Unlock the full IGC picture
About IGC Pharma, Inc.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC stock facts
| Ticker symbol | IGC |
| Exchange | New York Stock Exchange Arca |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $28.3M |
| CEO | Ram Mukunda |
| Employees | 70 |
| Headquarters | Potomac, MD, US |
| IPO date | 2006-05-24 |
| Website | igcpharma.com |
What you can see for IGC on Tickr
Live IGC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IGC report.
Rankings
FAQ
What is the ticker symbol for IGC Pharma, Inc.?
The ticker symbol for IGC Pharma, Inc. is IGC, listed on the New York Stock Exchange Arca.
What is IGC?
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related…